Physician profile
Kai E Jones
NPI 1427618578
$3,901.07
in general payments reported to CMS, 2019-2025
9 companies · $3,326 in 2025
The $3,326 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.03 · 2023: $14.11 · 2024: $520 · 2025: $3,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,820 · Food and Beverage: $1,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,820.00 |
| Food and Beverage | $1,040.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $3,010.30 | 2025 | |
| Beta Bionics, INC. | $323.29 | 2024 | Ilet Bionic Pancreas |
| Lilly USA, LLC | $146.66 | 2022-2025 | Zepbound |
| Medtronic, INC. | $125.00 | 2024 | Minimed 780g |
| Tandem Diabetes Care, INC. | $114.75 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $78.48 | 2025 | |
| Novo Nordisk INC | $71.33 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.15 | 2022 | |
| Dexcom, INC. | $14.11 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kai Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.